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A B S T R A C T
Cognitive impairment is one of the core symptoms of schizophrenia, and patients with schizophrenia are at
increased risk of metabolic syndrome (MS). However, the role of MS in cognitive impairment of schizophrenia is
not established. This study investigated the correlation between neurocognitive, social cognitive performance
and MS with schizophrenia. One hundred and fifty eight (158) schizophrenia patients were divided into 3 groups
with ① normal metabolism, ② metabolic disorder (only meeting 1 or 2 MS criteria), and ③ metabolic syndrome
(meeting 3 or more MS criteria). MATRICS Consensus Cognitive Battery)MCCB(and the Brief Psychiatric Rating
Scale)BPRS(were used to evaluate cognitive performance and clinical symptoms. Blood samples were obtained
to detect glucose and lipid metabolic levels. Overall MCCB and subscale T scores in the normal metabolism and
metabolic disorder groups were better than in the MS group. After controlling for the confounding factors in-
cluding age, sex, the usage of hypolipidemic and hypoglycemic drugs, and disease duration, metabolic deficits
had effects on the symbol coding and spatial span scores. The results suggest that a defective metabolic state
might play a role in neurocognitive performance of schizophrenia patients.
1. Introduction
Cognitive impairment is one of core symptoms of schizophrenia,
mainly neurocognition and social cognition. Cognitive dysfunction
significantly affects social performance and overall prognosis (Wu et al.,
2016). Many factors can affect cognitive performance; metabolic syn-
drome (MS) is one of the factors (Chen et al., 2016). In fact, the in-
cidence of metabolic syndrome in schizophrenia is twice that in the
general population (Wu et al., 2013).
A number of studies (Boyer et al., 2014, Boyer et al., 2013) have
established that MS can impair neurocognitive performance in schizo-
phrenia patients. The latest Meta-analysis (Bora et al., 2017) reported
that schizophrenia patients with MS and diabetes had more serious
cognitive deficits than those without these metabolic disorders, while
MS patients had much poorer memory, poor attention, low processing
speed, and poor execution. There is a significant correlation between
cognitive dysfunction and MS components including hypertension,
dyslipidemia, abdominal obesity, and diabetes in schizophrenia pa-
tients. Chinese population studies have also shown much more severe
neurocognitive impairment in schizophrenia patients with MS (Li et al.,
2014).
However, it is controversial and inconclusive as to which neuro-
cognitive dimensions can be affected more significantly by MS, and
whether metabolic syndrome can aggravate social cognition of schizo-
phrenia patients and is still rarely reported. In light of these questions,
this study aims to find the possible correlation between MS and overall
cognitive performance, and different cognitive dimensions, in schizo-
phrenia patients. This will provide a theoretical basis to answer these
questions and help to improve cognitive performance in schizophrenia
patients from the perspective of metabolism.
2. Material and methods
2.1. Participants
The study included 158 patients with schizophrenia who were ad-
mitted to the psychiatry department at the Third Affiliated Hospital of
Sun Yat-sen University, from May 2017 to October 2017, and who were
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receiving antipsychotic medications for 1 year or more. Inclusion cri-
teria for patients with schizophrenia included (1) Meeting diagnostic
criteria for schizophrenia (ICD-10); (2) Aged 16 to 55 years, male or
female; (3) Having 1 year or longer course of illness and currently in a
chronic state; (4) Receiving antipsychotic medications, either as a
single agent or as a combination therapy, either with first generation
antipsychotics (FGAs) or second generation antipsychotics (SGAs). (5)
Have had a period of six or more years of education; (6) Family
members or legal guardians of patients fully understood the study
contents and had given written, informed consent.
Exclusion criteria for patients with schizophrenia included (1)
History of receiving immunosuppressant therapy or taking steroids in
the last three months; (2) History of other mental illnesses (such as
mood disorders, anxiety, eating disorders, substance abuse, or in-
tellectual disability); (3) Hearing and visual disturbances; (4) Have a
history of serious or chronic physical disease (including heart failure,
thyroid dysperformance, chronic hepatitis, and metabolic disease his-
tory); (5) Pregnancy or lactation in women.
2.2. Diagnostic criteria for metabolic syndrome (MS)
The study employed the unified definition of metabolic syndrome
assessed as per the Joint Interim Statement (JIS) definition
(Alberti et al., 2009), which requires three out of five of the following
risk factors: (1) Abdominal circumference criteria for Asians
(Grundy et al., 2005): male≥90 cm, female≥80 cm. (2) Hypertension
(≥130 mmHg for systolic blood pressure or ≥85 mmHg for diastolic
blood pressure) or on hypertensive medication. (3) Raised fasting blood
glucose≥5.6 mmol/L or on diabetic medication. (4) Raised fasting
triglyceride≥1.7 mmol/L. (5) Low high-density lipoprotein cholesterol
(HDL-C) [<1.0 mmol/L for men, <1.3 mmol/L for women]. Applying
the MS criteria, patients were divided into 3 groups ① normal meta-
bolism (meeting none of the MS diagnostic criteria), ② metabolic dis-
order (only meeting 1 or 2 MS diagnostic criteria), and ③ metabolic
syndrome (meeting 3 or more MS diagnostic criteria).
2.3. Evaluation tools
2.3.1 Survey of Demographic and General Clinical Data. We used a
self-made questionnaire to obtain general data including age, sex,
ethnicity, illness duration, number of hospitalizations, previous treat-
ment with antipsychotics and type, duration and dose of medication,
years of schooling, lifestyle (smoking, drinking history, exercise vo-
lume/week), whether taking medications which control blood pressure,
blood lipids and glucose and for how long. The weight, height, waist
circumference, blood pressure, glucose and lipid metabolism indicators
of all subjects were tested and collected by a specific researcher.
2.3.2 MATRICS Consensus Cognitive Battery (MCCB) The MATRICS
Consensus Cognitive Battery (MCCB) includes 10 subtests: Continuous
Performance Test- Identical Pairs, Trail Marking Test Part A, Category
Fluency, Symbol Coding, Hopkins Verbal Learning Test (HVLT), Brief
Visuospatial Memory Test (BVMT), The Third Version Wechsler
Memory Scale-Spatial Span, Digital Sequence, Neuropsychological
Assessment Battery (NBA), and the Managing Emotions of Mayer-
Salovey-Caruso Emotional Intelligence Test (MSCEIT). MCCB includes
seven cognitive domains: attention/vigilance, information processing
speed, verbal learning, visual learning, working memory, reasoning and
problem solving, and social cognition. MCCB is used worldwide, and is
recommended by the US Food and Drug Administration (FDA) for as-
sessing cognitive performance of patients with schizophrenia. All sub-
scales were converted to T scores based on the raw score (mean 50,
standard deviation 10). The MCCB total score is the sum of the sub-
scales and converted into T points. The higher the T score of subscales
and total T score, the better the cognitive performance.
2.3.3 The Brief Psychiatric Rating Scale (BPRS) is a scale for assessing
the severity of psychotic symptoms and is suitable for the majority of
patients with severe psychotic symptoms, especially for patients with
schizophrenia. There are 18 items in total and consists of five sub-fac-
tors, namely anxiety and depression, lack of vitality, thinking disorder,
activation, and hostile suspicion. The total score reflects the severity of
the psychotic symptoms. The higher the BPRS score, the more severe
the disease.
2.3.4 ICD-10 and mini-SCID patients/non-patients version are used to
diagnose and recruit schizophrenia patients and healthy controls. Mini-
International Neuropsychiatric Interview (MINI) designed by Sheehan
and Lecrubier is a short structured interview questionnaire for
International Classification of Mental and Behavioural Disorders, 10th
Revision (ICD-10). MINI has very good reliability, very good validity,
and very good researcher consistency. The interview time is obviously
shorter than SCID. The work is in the charge of chief psychiatrist Zili
Han. Through case review, all patients had previously been diagnosed
with schizophrenia, and at the time of enrollment, the diagnosis of
schizophrenia was confirmed again by retrospective evaluation of mini-
SCID. All healthy subjects were and are not eligible for any type of
mental disorder in ICD-10 after mini-SCID evaluation.
2.4. Research process
The schizophrenia diagnosis process was conducted by an associate
chief physician in the Psychiatry Department, who used the mini-SCID
procedure according to the ICD-10 diagnostic criteria. In order to ac-
curately study the effects of metabolisms on cognitive performance, all
schizophrenia patients in our study were divided according to MS cri-
teria into normal metabolism (meeting none of the MS diagnostic cri-
teria), metabolic disorder (only meeting 1 or 2 items of the MS diag-
nostic criteria) and metabolic syndrome (meeting 3 items or more of the
MS diagnostic criteria). An attending physician evaluated the BPRS of
all subjects and used a self-made general data questionnaire to collect
demographic data such as age, gender, education, and lifestyle of all
study subjects. The weight, height, waist circumference and blood
pressure of all subjects were measured by a specific researcher. Finally,
MCCB assessment was performed by another attending physician.
Metabolic parameters such as fasting blood glucose and lipids for all
participants were collected after 10 h fasting on the next morning by a
nurse. All participants voluntarily attended this study and gave written
informed consent to participating in this study. The Ethics Committee of
the Third Affiliated Hospital of Sun Yat-sen University approved this
study protocol.
2.5. Statistical analysis
The distribution of the variables was assessed using the Shapiro-
Wilk test. Normally distributed continuous variables were presented as
mean ± standard deviation (SD), demographic and general clinical
data were tested by one-way analysis of variance (ANOVA). Skewed
distributed continuous variables were tested by a rank-sum test or
Kruskal–Wallis H test. The Chi-square test was used for category vari-
ables. Fisher's least significant difference (LSD) test was used to perform
post-hoc pair-wise comparison between groups of normal metabolism,
metabolic disorder and metabolic syndrome. Meanwhile, ANCOVA was
used to test the effects of metabolic conditions on cognitive perfor-
mance, while age, sex, hypolipidemic and hypoglycemic drugs, anti-
psychotic drug doses, and disease duration were used as confounding
factors. Finally, Multiple Linear Regression was used to investigate the
effect of individual component of MS on cognitive performance. All
statistical analyses were performed using the IBM SPSS 23.0 software
package. All p-values were two tailed with significance level set at
0.05.
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3. Results
3.1. The comparison of demographic and general clinical data between
schizophrenia patients with normal metabolism, metabolic disorder and
metabolic syndrome
Table 1. shows the demographic information of all subjects. Among
158 patients with schizophrenia, 37 patients had normal metabolism,
63 patients met the metabolic disorder criteria but did not reach the MS
criteria, and 58 patients met the MS criteria. The prevalence of MS was
37.61%. The average age of the normal metabolism group was
23.78 ± 5.07 years, and the average disease duration was
65.54 ± 50.46 months. The average age of the metabolic disorder
group was 28.10 ± 7.82 years, and the average disease duration was
76.59 ± 50.10 months. The average age of the metabolic syndrome
group was 31.41 ± 7.59, and the average disease duration was
93.33 ± 74.76 months. The use of hypolipidemic and hypoglycemic
drugs in patients with metabolic syndrome was higher than in the other
two groups (Table 1).
There were significant differences between three groups in age, the
usage of hypolipidemic and hypoglycemic drugs, and the disease
duration (Table 1). However, there was no significant difference be-
tween the three groups in the categories of sex, smoking, drinking,
exercise, years of education, antipsychotic drug doses, antihypertensive
drug, drug compliance, and the BPRS total score (all p>0.05) (Table 1).
3.2. The comparison of cognitive performance between patients with normal
metabolism, metabolic disorder and metabolic syndrome
Overall MCCB total T scores and subscale T scores of the metabolic
syndrome group were the lowest, while the metabolic disorder group
was much lower than the normal group. Since there were significant
differences in age, the use of hypolipidemic and hypoglycemic drugs,
and disease duration between the three groups (Table 1), the con-
founding factors (including age, sex, hypolipidemic, hypoglycemic
drugs, antipsychotic drug doses, and disease duration) were controlled
for ANCOVA test. ANCOVA showed significant main effects of meta-
bolic factors on SC (F(2155) = 3.426, p = 0.035), and SS (F
Table 1
Demographic and general clinical data among three groups of patients with schizophrenia.
Variable Normal metabolism① (n = 37) Metabolic disorder② (n = 63) Metabolic syndrome③ (n = 58) F/χ2 P ①VS② ①VS③ ②VS③
Age(yrs) 23.78(5.07) 28.10(7.82) 31.41(7.59) 23.480 <0.001 0.004 <0.001 0.012
Education(y) 13.43(2.62) 13.21(3.10) 12.90(3.08) 0.804 0.669
Sex
Male 17(45.95%) 27(42.86%) 34(58.62%) 3.228 0.199
Female 20(54.05%) 36(57.14%) 24(41.38%)
Smoking
Yes 2(5.41%) 8(12.70%) 13(22.41%) 5.510 0.064 0.407 0.054 0.159
No 35(94.59%) 55(87.30%) 45(77.59%)
Drinking
Yes 1(2.70%) 2(3.17%) 5(8.62%) 2.408 0.300
No 36(97.30%) 61(96.83%) 53(91.38%)
Exercise
Yes 16(43.24%) 20(31.75%) 14(24.14%) 3.788 0.150
No 21(56.76%) 43(68.25%) 44(75.86%)
Antihypertensive drug 0)0%( 0)0%( 1)1.72%( 1.724 0.422
Hypolipidemic drug 0)0%( 0)0%( 4)6.90%( 7.031 0.030 0.000 0.154 0.050
Hypoglycemic drugs 0)0%( 1)1.59%( 9)15.52%( 13.206 0.001 1.000 0.011 0.007
Antipsychotic drugs dose(DDD) 330.59(200.57) 425.21(244.15) 402.70(226.70) 2.872 0.238
Disease duration(m) 65.54(50.46) 76.59(50.10) 93.33(74.76) 2.570 0.080 0.379 0.030 0.130
Drug compliance 6.57(1.63) 6.54(1.72) 6.48(1.43) 0.399 0.819
BPRS total score 30.03(8.83) 29.73(10.46) 29.60(7.64) 0.637 0.727
DDD means Drug dose was chlorpromazine equivalence (Gardner et al. 2010).
Table 2
The neurocognitive and social cognitive performance difference between groups of patients with schizophrenia (ANCOVA).
Groups
Variable Normal metabolism① Metabolic disorder② Metabolic syndrome③ ①VS② ①VS③ ②VS③ F P
(n = 37) (n = 63) (n = 58)
Means(SE) Means(SE) Means(SE)
Information processing speed
TMT 47.51(2.05) 47.57(1.49) 44.99(1.63) 0.980 0.361 0.253 0.735 0.481
SC 38.00(2.03) 35.18(1.48) 31.08(1.62) 0.263 0.012 0.068 3.426 0.035
CF 39.68(1.56) 39.10(1.14) 37.79(1.24) 0.761 0.367 0.446 0.473 0.624
Verbal learning(HVLT) 34.38(2.56) 33.03(1.86) 30.21(2.04) 0.670 0.227 0.318 0.837 0.435
Working memory
SS 37.30(2.56) 41.96(1.87) 35.20(2.04) 0.143 0.544 0.018 3.112 0.047
DS 40.43(2.34) 41.33(1.70) 37.09(1.86) 0.757 0.287 0.101 1.402 0.249
Reasoning and problem solving(NAB) 40.36(2.89) 40.23(2.10) 40.66(2.30) 0.970 0.940 0.893 0.009 0.991
Visual learnin(BVMT) 38.54(2.48) 39.59(1.81) 35.30(1.98) 0.732 0.333 0.118 1.260 0.287
Attention/vigilance(CPT) 39.83(2.09) 38.82(1.52) 35.36(1.66) 0.694 0.113 0.134 1.603 0.205
Social cognition(MSCEIT) 51.13(2.53) 50.51(1.84) 50.46(2.01) 0.844 0.844 0.985 0.024 0.977
Overall Cognition (MCCB) 33.33(2.61) 34.26(1.90) 28.61(2.08) 0.774 0.181 0.051 2.014 0.137
TMT: trail making A test; SC: symbol coding test; HVLT: Hopkins verbal learning test; SS: spatial span; DS: digital sequence; NAB: Neuropsychological Assessment
Battery (NAB); BVMT: brief visual spatial memory test; CF: category fluency; CPT: Continuous Performance; MSCEIT: Mayer-Salovey-Caruso Emotional Intelligence
Test; MCCB: MCCB total score.
Age, sex, hypolipidemic, hypoglycemic drugs, antipsychotic drug doses, and disease duration were controlled as covariates in this data analysis.
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(2155) = 3.112, p = 0.047). Further post-hoc analysis showed that
patients with normal metabolism has significant higher SC scores than
those with metabolic syndrome (p = 0.012), while patients with me-
tabolic disorder had significant higher SS scores than metabolic syn-
drome group (p = 0.018) (Table 2).
3.3. The effect of different components of MS on cognitive performance
The total T scores and subscale T scores of MCCB for schizophrenia
patients were used as dependent variables, while age, sex, hypolipi-
demic and hypoglycemic drugs, antipsychotic drug doses, disease
duration, and glucose and lipid metabolism parameters were set as
independent variables for multiple linear regression analysis (Table 3).
We found that systolic blood pressure significantly influenced HVLT,
NAB, CPT, and MCCB total score (p < 0.05), while diastolic blood
pressure had significant impacts on HVLT, NAB, and BVMT (p < 0.05).
TG had significant impacts on HVLT, SS, and BVMT. Meanwhile, PFG
significantly influenced DS and CF. AC and HDL-C had effects on SC and
BVMT, respectively (p < 0.05) (Table 3).
4. Discussion
This study found that a defective metabolic state played a role in the
neurocognitive performances of schizophrenia patients. After control-
ling the confounding factors (age, sex, antipsychotic dose, disease
duration, and the use of hypolipidemic and hypoglycemic drugs),
ANCOVA found that metabolic states had effects on SC and SS in
chronic schizophrenia patients (Table 2). These results suggested that a
defective metabolic state might exacerbate the neurocognitive deficits
of schizophrenia, especial in SC and SS. Divergent cognitive impair-
ments have been reported previously in schizophrenia patients with MS
compared to those without MS (Boyer et al., 2014, Li et al., 2014,
Lindenmayer et al., 2012). For example, Kern (Kern et al., 2011) re-
ported that, while reasoning and problem solving were less impaired,
processing speed and working memory were serious damaged in schi-
zophrenia patients. Ojeda et al. (Ojeda et al., 2012) has found that, after
controlling information processing speed, working memory is no longer
manifested as a unique feature of schizophrenia, suggesting that de-
creased processing speed may be the core cognitive deficits of schizo-
phrenia. In this study, we also found that MS may have an effect on the
symbol coding T score. Therefore, we cautiously speculated that MS
slightly possibly affect information processing speed in patients with
schizophrenia.
Recently, Eyler and Jeste reported (Eyler and Jeste 2017) that
cognitive therapy and MS management may contribute to delay cog-
nitive decline in schizophrenia patients. It is well established that the
incidence of MS in chronic schizophrenia patients is 2–4 times that in
the general population, while the patient's MS is hard to be reversed,
even after stopping antipsychotic treatment (Wu et al., 2014). Evidence
from this and previous studies indicates that early management of
metabolic risk in schizophrenia patients is beneficial to the improve-
ment of their core cognitive deficits (information processing). There-
fore, it is critical in clinical practice to monitor regularly the glucose
and lipid metabolic parameters during antipsychotic treatment, to
guide for a healthy lifestyle, and to delay or block MS progresses, in
order to prevent MS from aggravating cognitive deficits in schizo-
phrenia patients.
The study subjects were divided into three groups according to the
items meeting the MS diagnostic criteria. Schizophrenia patients with
MS and metabolic disorder had much worse cognitive impairment in
symbol coding than that of schizophrenia patients with normal meta-
bolism. Studies on the general population showed that cognitive per-
formance would be worse with the increase of items meeting the MS
criteria (Li et al., 2016). At the same time, the accumulation of three or
more cardiovascular risk factors (such as, obesity, hypertension, dia-
betes, and dyslipidemia) can increase the incidence of mild cognitiveTa
bl
e
3
M
ul
ti
pl
e
Li
ne
ar
R
eg
re
ss
io
n
an
al
ys
is
of
fa
ct
or
s
aff
ec
ti
ng
co
gn
it
iv
e
pe
rf
or
m
an
ce
in
sc
hi
zo
ph
re
ni
a
pa
ti
en
ts
.
TM
T
SC
H
V
LT
SS
D
S
N
A
B
BV
M
T
C
F
M
SC
EI
T
C
PT
M
C
C
B
B
P
B
P
B
P
B
P
B
P
B
P
B
P
B
P
B
P
B
P
B
P
A
C
0.
01
0
0.
92
9
−
0.
29
1
0.
00
8
−
0.
02
4
0.
85
2
−
0.
05
7
0.
68
3
−
0.
13
4
0.
28
1
−
0.
05
3
0.
72
5
−
0.
07
6
0.
54
4
−
0.
01
8
0.
82
9
0.
01
6
0.
90
6
−
0.
14
0
0.
20
2
−
0.
14
2
0.
29
9
SB
P
0.
01
7
0.
88
2
0.
09
0
0.
41
2
0.
28
8
0.
03
3
0.
05
8
0.
68
3
0.
02
6
0.
84
0
0.
33
9
0.
02
8
0.
22
2
0.
08
4
0.
09
7
0.
24
8
0.
17
0
0.
21
4
0.
24
3
0.
03
0
0.
30
4
0.
02
9
D
BP
−
0.
02
6
0.
84
7
−
0.
04
2
0.
75
1
−
0.
39
3
0.
01
5
−
0.
10
4
0.
54
3
0.
02
3
0.
87
9
−
0.
40
8
0.
02
8
−
0.
48
0
0.
00
2
−
0.
08
1
0.
42
5
−
0.
00
7
0.
96
6
−
0.
15
9
0.
23
4
−
0.
30
4
0.
07
0
TG
−
1.
45
5
0.
21
0
0.
13
4
0.
90
6
−
3.
14
2
0.
02
4
−
2.
93
7
0.
04
7
−
0.
65
0
0.
62
1
0.
02
7
0.
98
7
−
4.
00
7
0.
00
3
−
0.
98
5
0.
25
9
−
1.
47
3
0.
29
8
−
2.
19
4
0.
05
8
−
2.
84
7
0.
04
9
H
D
L-
C
−
0.
30
1
0.
94
7
2.
32
6
0.
60
2
2.
95
4
0.
58
7
−
5.
87
5
0.
31
0
0.
81
9
0.
87
4
3.
29
4
0.
59
8
−
10
.8
31
0.
03
9
−
1.
41
1
0.
68
0
−
1.
57
0
0.
77
7
−
3.
21
1
0.
47
8
−
1.
08
3
0.
84
8
PF
G
−
1.
66
9
0.
18
4
−
1.
49
1
0.
22
5
−
0.
16
7
0.
91
1
0.
11
9
0.
94
0
−
3.
15
7
0.
02
7
−
2.
71
7
0.
11
5
−
0.
77
6
0.
58
8
−
2.
12
2
0.
02
5
−
2.
42
7
0.
11
3
−
2.
22
6
0.
07
5
−
1.
96
4
0.
20
7
TM
T:
tr
ai
lm
ak
in
g
A
te
st
;S
C
:s
ym
bo
lc
od
in
g
te
st
;H
V
LT
:H
op
ki
ns
ve
rb
al
le
ar
ni
ng
te
st
;S
S:
sp
at
ia
ls
pa
n;
D
S:
di
gi
ta
ls
eq
ue
nc
e;
N
A
B:
N
eu
ro
ps
yc
ho
lo
gi
ca
lA
ss
es
sm
en
t
Ba
tt
er
y
(N
A
B)
;B
V
M
T:
br
ie
fv
is
ua
ls
pa
ti
al
m
em
or
y
te
st
;
C
F:
ca
te
go
ry
fl
ue
nc
y;
C
PT
:C
on
ti
nu
ou
s
Pe
rf
or
m
an
ce
;M
SC
EI
T:
M
ay
er
-S
al
ov
ey
-C
ar
us
o
Em
ot
io
na
l
In
te
lli
ge
nc
e
Te
st
;M
C
C
B:
M
C
C
B
to
ta
l
sc
or
e;
SB
P:
Sy
st
ol
ic
bl
oo
d
pr
es
su
re
;D
BP
:D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
;A
C
:A
bd
om
in
al
ci
rc
um
fe
re
nc
e.
TG
:T
ri
gl
yc
er
id
es
;H
D
L-
C
:H
ig
h
de
ns
it
y
lip
op
ro
te
in
ch
ol
es
te
ro
l;
PF
G
:P
la
sm
a
fa
st
in
g
gl
uc
os
e.
S. Chen, et al. Psychiatry Research 288 (2020) 112941
4
impairment in elderly patients by 1.58 times, and the risk from mild
cognitive impairment to dementia by 4.92 times (Ng et al., 2016).
These studies suggest there is a cumulative effect of metabolic deficits
on cognitive impairment. Our further analysis found that with the in-
crease of items meeting MS criteria, cognitive performance also tends to
worsen. The result suggests that MS may further worsen cognitive
performance in patients with schizophrenia, especially in the SC cog-
nitive dimension.
In order to further explore the effect of different MS parameters on
cognitive performance in chronic schizophrenia patients, a multiple
linear regression analysis was conducted and showed that neurocog-
nitive performance was correlated with FPG, HDL-C, SBP, DBP, AC and
TG. Particularly, the blood pressure (including systolic blood pressure
and diastolic blood pressure) had effects on processing speed, working
memory, reasoning and problem solving, verbal learning, visual
learning and MCCB total scores. These findings were consistent with
previous reports that fasting plasma glucose and blood pressure levels
were significantly associated with cognitive impairments in processing
speed, verbal learning, visual learning, and executive ability in schi-
zophrenia (Goughari et al., 2015, Sabayan et al., 2013, Tsai et al.,
2016). In fact, antihypertensive drugs could increase cerebral blood
flow and improve neurocognitive performance in the patients with MS
(Efimova et al., 2015).
A cross-sectional study reported that differences in social cognitive
performance existed between pre-onset, acute phase, and chronic
schizophrenia patients, and suggested that social cognitive impairment
should occur early in the disease, and later in the disease there should
be no further impairment or even improvement (Green et al., 2012). A
prospective study conducted a one-year follow-up of first-episode
schizophrenia patients and found that they maintained a relatively
stable level of social cognitive performance after the acute phase
(Horan et al., 2012). Social cognitive impairment in the acute phase
was much worse than patients, in remission (Valaparla et al., 2017).
This study found no significant effect of defective metabolism on the
social cognition performance in chronic schizophrenia patients. Pre-
sumably this result may be due to: ① the subjects studied were chronic
and stable schizophrenia patients, however social cognitive perfor-
mance was significantly impaired in an acute phase of first onset and
remained relatively stable at chronic phase. ② MS may affect neuro-
cognitive performance, but might have minimal effects on social cog-
nition. Although the MS group had significantly decreased neurocog-
nitive scores including processing speed, digital sequence, working
memory, attention, verbal learning, and visual learning, no significant
differences were found between MS and non-MS group in terms of so-
cial cognition performance. ③ This study subjects were younger, and
some patients had a shorter duration of metabolic syndrome, or they
had already partially received drugs for intervention. As a result, our
study did not find that MS has a widespread role in the deterioration of
cognitive performance, especially in social cognition. (Akbaraly et al.,
2010) reported that among people aged 33–55 years, the cognitive
performance of participants with persistent MS during a 10 year follow-
up period was worse than participants without MS, and no significant
difference in cognitive performance was observed between those with
non-persistent MS and those who never had MS during follow-up. ④ It is
also worthy to note that the Managing Emotions of Mayer-Salovey-
Caruso Emotional Intelligence Test (MSCEIT) in MCCB is far from a
complete picture of social cognition in schizophrenia. Managing emo-
tions is just one of social cognitive domains, including affect perception,
social cue perception, theory of mind, empathy, and attribution style.
Therefore, a comprehensive tool for social cognitive assessments is
important in the future to explore the full picture of social cognition in
chronic schizophrenia patients with defective metabolism.
5. Limitations
One limitation of this study is a relatively small sample size which
may decrease our study efficiency, but increase the risk of false negative
findings. On the other hand, as a cross-sectional study, it cannot easily
distinguish the direction of relationships between cognitive perfor-
mance and MS poor cognitive performance might be also a risk marker
for developing MS due to poor decision making. Furthermore, it is
worthy to note another significant limitation in this study that, due to
lack of correction for multiple comparisons, we could not completely
rule out the potential false positive findings reported in this paper.
Therefore, a prospective, longitudinal study with adequate power in the
future is necessary to confirm the findings in this study.
6. Conclusion
In summary, this study suggests that a defective metabolic state
might play a role in neurocognitive performance of patients with
schizophrenia, especially in the symbol coding and spatial span scores,
either from the point of view of MS or the point of view of individual
MS components. This may provide an opportunity for more precise
clinical interventions aimed at cognitive deficits in chronic schizo-
phrenia patients.
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